Axial Disease and Psoriasis Increasingly Linked
Axial disease seems to increasingly depend on the presence of skin psoriasis and HLA-B*27 alleles, researchers write in ARD.
2016 Psoriasis Treatment Guidelines Issued
New treatment guidelines for plaque psoriasis have been issued in the U.S. where 50 percent of patients say they are dissatisfied with treatment.
Psoriasis Patients Require Annual PsA Screening
Up to 30% of psoriasis patients will develop psoriatic arthritis. Studies show that a proportion of patients in clinical care have undiagnosed PsA.
Increased Risk of Leukemia Associated with an Autoimmune Disease Treatment
Researchers reporting at the American Society of Hematology annual meeting this week say there is a link between a treatment for autoimmune disease and the development of leukemia.
Apremilast vs CF101 for Psoriasis
Researchers find that apremilast and CF101 both are safe and effective for psoriasis, but apremilast outperforms CF101 through 16 weeks, until it plateaus.
Safety Data from RA Studies Doesn’t Always Apply to Psoriasis Patients
Safety results from studies of rheumatoid arthritis patients are not fully applicable to psoriasis patients, recent studies show.
Induction Period for Switching Biologics in Psoriasis Recommended
Patients with moderate-to-severe psoriasis who switch biologic medications at the end of a clinical trial should go through an induction period.
Adalimumab-atto: It’s Indications and Key Takeaways
In this slideshow, we summarize the newly approved indications for Amgen's new biosimilar, adalimumab-atto (Amjevita) and, we highlight key points as stated by Amgen researchers.
10 Points to Consider when Evaluating your PsA Patients
Some new and old concepts to consider when evaluating patients with severe psoriatic arthritis (PsA) for cardiovascular diseases.
By clicking Accept, you agree to become a member of the UBM Medica Community.